Monique Andersson is Senior Lecturer in the Division of Medical Virology, University of Stellenbosch, South Africa and Clinical fellow in Microbiology and Infectious Diseases at Oxford University Hospitals, UK. Her main research interest is viral hepatitis in SSA, in particular MTCT of HBV. She teaches Virology to undergraduates and postgraduates.
Organizing Committee / Co-convener of HCV access theme
Dr. Isabelle Andrieux‐Meyer works as an HIV and hepatitis C Medical Advisor at the Access Campaign of Doctors Without Borders (MSF) and resides in Geneva, Switzerland. She also serves as the Médecin Invité in Geneva University Hospital, Infectious Disease consultation; and studies epidemiology at the London School of Hygiene and Tropical Medicine.
Organizing Committee / Co-convener of Epidemiology and disease burden theme
Dr. Anchalee Avihingsanon is Head of Medical Department at the HIV Netherlands Australia Thailand Research Collaboration . She is on the writing committee for Thai HIV Treatment Guidelines, and a member of Track B planning the 2013 International Congress on AIDS in Asia and the Pacific. She advises the TRC-ARC’s Community Advisory Board (CAB).
Dr. Andrew Ball is the Senior Strategy and Operations Adviser in the WHO HIV/AIDS Department in Geneva, where he heads up the Policy, United Nations Coordination and External Relations units. Dr Ball is a physician trained in addiction medicine. A national of Australia, he has over 25 years of clinical and public health experience in HIV/AIDS, substance dependence and adolescent health, including almost 20 years of international experience.
Dr. Wilbert Bannenberg is a Public Health Physician and Pharmaceutical systems expert with Hera Foundation. He has experience with National Drug Policy development and implementation support, access to essential medicines, regulatory systems support, intellectual property rights issues and medicines in Africa. He worked 5 years as coordinator of the South African Drug Action Programme, and 4 years as part-time team leader of the Drug Safety Project in Mongolia.
Dr. Sanjay Bhagani is a consultant physician in infectious diseases and HIV medicine and senior lecturer at Royal Free Hospital, London. He has a special interest in the management of complex HIV infection, including difficult opportunistic infections and the management of viral hepatitis in HIV-infected patients.
Dr. Christoph Boesecke is currently working as an Infectious Diseases Specialist and Clinical Research Fellow at the University of Bonn, Germany. His main areas of research are focused on co-morbidities and co-infections in HIV, particularly acute Hepatitis C.
Dr. Julie Bruneau is a clinical researcher and Professor in the Department of family medicine at the University of Montreal. As a clinician, she is recognized as a leader in the development of addiction medicine in Canada. Her research accomplishments have significantly contributed to a better understanding of the dynamics of HIV and HCV transmission among injection drug users.
Dr. Henry Chan is a professor in the Department of Medicine and Therapeutics at the Chinese University of Hong Kong, in addition to being the head of the Gastroenterology and Hepatology division, and the director of the Institute for Digestive Health and the Centre for Liver health. His expertise lies primarily in Gastroenterology and Hepatology.
Organizing Committee / Co-convener of HCV therapeutic development theme
Dr. Curtis Cooper is currently an Associate Professor with the University of Ottawa, Infectious Diseases Consultant with the Ottawa Hospital Division of Infectious Diseases, and Associate Clinical Researcher with the Ottawa Hospital Research Institute. As a clinical researcher, his research activities encompass HIV, viral hepatitis, and vaccine development. His work is focused on the development of new therapeutic agents and the delivery of treatment that maximizes safety, adherence and safety. Curtis is an OHTN Career Scientist and Core Co-leader of the CTN Co-infections and concurrent diseases core.
Dr. Pierre Coté is a Physician at Clinique médicale du Quartier Latin. He is the President of the National AIDS/HIV Mentoring Program (PNMVS) and Coordinator of the UHRESS-CHUM Outreach Team.
Organizing Committee / Convener of treatment in special populations theme
Professor Gregory Dore is Head of the Viral Hepatitis Clinical Research Program, Kirby Institute for infection and immunity in society, The University of New South Wales and an Infectious Diseases Physician at St Vincent’s Hospital, Sydney, Australia. He has been involved in the hepatitis C sector for 15 years, in academic research, clinical, and public health policy capacities. Dr. Gore acts as convener for the treatment in special populations theme at the conference.
Organizing Committee / Convener of HBV prevention and management
Dr. Feld graduated from medical school at the University of Toronto in 1997 and then completed residency programs in Internal Medicine and Gastroenterology. Following his clinical training, Dr. Feld focused on developing skills in clinical and laboratory research in liver disease, with a particular interest in viral hepatitis. He completed a clinical research fellowship in hepatology and then spent 4 years doing clinical and laboratory research in the Liver Diseases Branch of the National Institutes of Health. He received a Masters of Public Health with a focus on Infectious Diseases as a Sommer Scholar from Johns Hopkins University and has worked extensively abroad, maintaining a strong interest in International Health. Currently, Dr. Feld is clinician-scientist based at the Toronto Western Hospital Liver Clinic and the McLaughlin-Rotman Centre for Global Health.
Dr. Peter Ghali is an assistant professor in the Department of Gastroenterology and Hepatology at McGill University. He is the Program Director for Hepatology and Liver Transplantation and the Site Director for the Royal Victoria Hospital Division of Gastroenterology and Hepatology at the McGill University Health Centre (MUHC) in Montreal. His research interests and areas of publication are post-transplantation outcomes, Hepatitis C, and fatty liver disease.
Dr. Massimo Ghidinelli is a trained physician with over twenty five years of experience in international public health, with focus on infectious and tropical diseases, including HIV and STI. He is the Pan American Health Organization / World Health Organization Project Coordinator of the Prevention, Treatment and Care for HIV/STI Project (FCH/HI), Area of Family and Community Health. He resides in Washington, DC.
Dr. Jason Grebely is an Associate Professor in the Viral Hepatitis Clinical Research Program at the Kirby Institute, UNSW Australia in Sydney. Research interests include epidemiology, natural history and therapeutic strategies for acute and chronic HCV infection in people who inject drugs.
Alissa Greer is a research coordinator for peer engagement in harm reduction at the BC Centre for Disease Control. Her research has been focused in harm reduction initiatives and drug policy in Canada and the United States for over a decade. She is a Bridge CIHR Strategic Training Fellow at the University of British Columbia and is completing her doctoral studies through the School of Population and Public Health.
Kathryn Gretsinger is the lead instructor in the School’s Integrated Journalism program. She also contributes to the International Reporting program and the Reporting in Indigenous Communities course. She also runs the School’s Internship program. She frequently guest hosts radio programs at CBC and continues to work with reporters, producers and editors to train journalists in audio storytelling techniques.
Herb Joseph Harwell
Dr. Joseph Harwell is an Associate Professor of Medicine and Pediatrics at Brown University and is the Asia Regional Clinical Officer for the Clinton Health Access Initiative. He is a medical doctor specializing in infectious diseases in adults and children. Dr. Harwell has been working in Southeast Asia for 12 years, particularly in Cambodia, China, Indonesia, Papua New Guinea, and Vietnam. His work has focused on HIV in women and children and on interventions to increase access to care for people living with HIV.
Dr. Andrew Hill is a senior visiting Research Fellow in the Pharmacology Department at Liverpool University, UK. His main research is on antiretroviral treatment for developing countries. He is an advisor to the Clinton Foundation and the Bill and Melinda Gates Foundation, designing clinical trial programmes of dose optimisation for antiretrovirals.
Dr. Mark Hull completed his Fellowship in Infectious Diseases at the University of British Columbia. He went on to complete a Postdoctoral Fellowship with the Canadian CIHR HIV Clinical Trials Network. He now works as clinician and Research Scientist at the BC Centre for Excellence in HIV/AIDS, with an interest in HIV/Hepatitis C co-infection. He is a co-investigator in the pan-Canadian Co-infection Cohort and the lead author on the Canadian co-infection management guidelines.
Karyn Kaplan is the Director of International Hepatitis/HIV Policy and Advocacy with the Treatment Action Group (TAG) in New York. In this role, she provides leadership and technical assistance to civil society advocates in low- and middle-income countries who are working to increase access to hepatitis C virus (HCV) prevention, care and treatment.
Dr. Alexandra King is a member of the Nipissing First Nation (Ontario). She is a specialist in Internal Medicine, in the process of establishing herself in independent practice. Her PhD at Simon Fraser University, is focused on intervention research at the nexus of health determinants, mental health and addictions, blood-born and sexually transmitted infections, and incarceration in Indigenous people in Canada.
Organizing Committee / Co-chair
Dr. Marina Klein is Professor of Medicine, McGill University, Montreal, Canada in the Division of Infectious Diseases/Chronic Viral Illnesses. Her clinical interests focus on treatment of patients with HIV and chronic viral hepatitis. Read more>
Dr. Karine Lacombe is currently holding the position of associate professor in the infectious and tropical diseases department of Saint-Antoine Hospital (AP-HP), Paris – France. She teaches infectious diseases and public health in numerous universities and schools around France, Sub Saharan Africa and the Asian continent.
Dr. Marc Lallemant is the Head of Paediatric HIV Programme for the Drugs for Neglected Diseases initiative (DNDi).He was the principal investigator of major NIH funded clinical trials, the results of which have served as the basis for WHO recommendations for PMTCT in resource-limited countries. He is also involved in the perinatal HIV and paediatric research programme of the Paediatric European Network for the Treatment of AIDS (PENTA) and the International Maternal Paediatric Adolescent AIDS Clinical Trials Group (IMPAACT).
Dr Ying-Ru Lo is the Coordinator for HIV, Hepatitis and STI at the World Health Organization, Regional Office for the Western Pacific in Manila. She is leading teams of experts to support national efforts in responding to the hepatitis B and C epidemics in China, Mongolia and Viet Nam. The teams are currently expanding collaboration with 37 Member States and Areas through a Regional Action Plan on Viral Hepatitis. Dr Lo is an infectious disease physician from Hamburg, Germany. She has about 30 years of experience in clinical management of infectious diseases and as senior public health expert at WHO. Her main interests are in translating research to implementation and generation evidence-based public health guidance.
Dr. Niklas Luhmann is a Harm Reduction and HIV/AIDS advisor for the French NGO Médecins du Monde (MdM) headquartered in Paris. For the past two years, he has worked increasingly on issues related to hepatitis C treatment access in low and middle income countries and France.
DenmarkDr. Jens Lundgren is Professor of Viral Diseases and a practicing infectious disease specialist. He founded, and heads, the Centre for Viral Diseases @ the department of infectious diseases and the Copenhagen HIV Programme (CHIP; http://www.cphiv.dk/), based at the Copenhagen University Hospital (Rigshospitalet) and at the University of Copenhagen, respectively.
Ludmila Maistat is Senior Programme Manager: Hepatitis/HIV Policy and Advocacy, International HIV/AIDS Alliance in Ukraine. She joined the Alliance in 2011 and is currently leading all-Ukrainian mobilization and advocacy campaigns uniting NGOs, activists, experts, lawyers, health care workers and patient groups from all over Ukraine with the aim to scale up access to HepC treatment in the country, EECA region and other countries where Alliance works. In 2015, together with the Alliance colleagues launched the Alliance Practice Center on HIV, Hepatitis, and Drug Use with aim to provide thought and knowledge leadership on harm reduction, HIV and hepatitis as a broader response to end the epidemics.
Natasha K. Martin is an Associate Professor in the Division of Global Public Health in the Department of Medicine at the University of California San Diego. She is also an Honorary Senior Lecturer at the University of Bristol. Dr. Martin is an infectious disease and economic modeler with over 15 years of experience modeling biological systems.
Speaker / Chair
Dr. Gail Matthews is Associate Professor and NHMRC fellow in the Viral Hepatitis Clinical Research Program at the Kirby Institute, Sydney. She also holds a clinical academic appointment in HIV and Infectious Diseases at St Vincent’s Hospital, Sydney.
Dr. Lawrence Mbuagbaw is an Assistant Professor, Department of Clinical Epidemiology & Biostatistics Research in Victoria. His interests are mother and child health, human immunodeficiency virus (HIV) care, health systems research, mHealth and health research methodology – with a focus on enhancing biostatistics and epidemiological techniques to improve health outcomes using pragmatic knowledge translation designs which may be quantitative, qualitative or mixed.
Dr. Fábio Mesquita is the director of the STI/AIDS and Viral Hepatitis Department in the Ministry of Health in Brazil where he leads the development of the new Guidelines on test and offer for HIV and the expansion of universal access to hepatitis C treatment. Dr. Mesquita founded the International Harm Reduction Association. In both Latin America and South East Asia where he spent eight years, he is recognized as a key player in the expansion of harm reduction programmes in settings where the HIV epidemic is driven by injection drug use.
Jean Michel Pawlotsky
Dr. Jean-Michel Pawlotsky MD, PhD is Professor of Medicine at the University of Paris-Est. He is the Director of the National Reference Center for Viral Hepatitis B, C and Delta and of the Department of Virology at the Henri Mondor University Hospital in Créteil, France, and Director of the Department of Molecular Virology and Immunology at the “Institut Mondor de Recherche Biomédicale“ (INSERM U955). He focuses on teaching, diagnosis and research in virology, primarily hepatitis viruses.
Organizing Committee / Speaker
Dr. Marion Peters is a Professor of Medicine at the University of California in SF, USA, and holds the John V. Carbone, M.D., Endowed Chair in Medicine. She is also Chief of Hepatology Research. Dr. Peters is especially interested in the immunology of chronic liver diseases, particularly viral and autoimmune hepatitis. Her research activities include studies of HIV and HCV co-infection and alcohol and HCV infection.
Priti Radhakrishnan is Co-Founder and Director of Treatment Access of I-MAK, a non-profit organization of lawyers and scientists representing the rights of low-income patients worldwide. I-MAK works to expand access to lower-cost generic medicines by address legal and policy barriers, by challenging unmerited drug patents, partnering with stakeholders to achieve law and policy reforms, conducting advocacy and generating evidence-based research on intellectual property. I-MAK’s patent challenges have a 90% success rate, and on just three HIV drugs alone, enabled cost savings of half billion dollars over a five year period. I-MAK has also been at the forefront of challenging and winning key patent challenges on sofosbuvir, most recently successfully enabling the rejection of the sofosbuvir patent in China.
Raghavan Sai Subhasree
Dr. Sai Subhasree Raghavan is president of SAATHII, a non-profit organization working towards universal access to quality HIV/AIDS prevention, care, support, and treatment services in eight states of India since 2000. Dr. Raghavan is an elected representative of civil society on the CCM of the Global Fund, and has been instrumental in ensuring active involvement of civil society and in developing oversight mechanisms.
Homie Razavi is the managing director at the Center for Disease Analysis (CDA), an organisation specialising in the study of complex and poorly understood diseases based in Colorado, USA. For the past 6 years, he has led a team of epidemiologists and modellers to quantify epidemiology of hepatitis C virus (HCV) and forecast the future impact of HCV disease burden.
Organizing Committee / Co-chair
Dr. Jürgen Rockstroh is Professor of Medicine and Head of the HIV Outpatient Clinic at the University of Bonn in Germany. In addition to his clinical practice, Dr. Rockstroh is involved in HIV research on: antiretroviral therapy, including new drug classes; the course of HIV disease in haemophiliacs; and HIV and hepatitis co-infection. He has been an investigator in multiple clinical trials of antiretroviral agents and treatments for HIV and hepatitis co-infection. Read more >
Dr. Mauro Schechter is professor of Infectious Diseases at the Department of Preventive Medicine of the Federal University of Rio de Janeiro, Brazil. He is also Adjunct Professor of Epidemiology at the Graduate School of Public Health at the University of Pittsburgh, and Associate in the Department of International Health, Bloomberg School of Hygiene and Public Health, Johns Hopkins University.
Convener of HCV therapeutic development theme
Dr. Mark Sulkowski is an Associate Professor of Medicine at the Johns Hopkins University School of Medicine, and the Medical Director of the Johns Hopkins University Center for Viral Hepatitis, Division of Infectious Diseases. He teaches students and fellows at the Infectious Diseases Consult Service and Viral Hepatitis Clinic.
Organizing Speaker / Convener of HCV access theme
Tracy Swan is Hepatitis/HIV Project Director at Treatment Action Group (TAG), where she combines her passion for social justice with her interest in research and policy. Ms. Swan works with allies around the world to oversee HCV drug development, and develop and promote policies to increase access to high-quality HCV information, diagnostics, care and treatment for all who need it.
Dan Werb is an epidemiologist working in HIV, addictions, and drug policy. He is an Assistant Professor (proposed) at the division of Global Public Health at the University of California, San Diego. He is also the Director of the International Centre for Science in Drug Policy.
Dr. David L. Wyles is an Associate Professor of Medicine in the Department of Medicine, Division of Infectious Diseases at the University of California, San Diego. Dr. Wyles’ research interests include the laboratory evaluation of new antiviral therapies for Hepatitis C virus (HCV), drug resistance to HCV antivirals, and HCV viral fitness. Clinically Dr. Wyles is involved in trials of novel therapies for chronic HCV and the care of patients co-infected with HIV-1 and HCV.
2nd International HIV/Viral Hepatitis Co-infection Meeting
Friday, July 17 – Saturday, July 18, 2015
CIHR Canadian HIV Trials Network
588 – 1081 Burrard Street
Vancouver, BC V6Z 1Y6
Toll Free: 1-800-661-4664